<DOC>
	<DOC>NCT00625872</DOC>
	<brief_summary>The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.</brief_summary>
	<brief_title>Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy</brief_title>
	<detailed_description />
	<criteria>Prepubertal boys between 6 and 10 years of age or girls between 6 and 9 years of age. Birth length and/or birth weightSDS adjusted to gestational age &lt; 2.0 (Voigt et al. 2002, Voigt et al. 2006 or Lawrence et al. 1989). Current heightSDS &lt; 2.5 (Brandt/Reinken 1992) and parental adjusted heightSDS below 1 (Hermanussen and Cole 2003). Growth velocity SDS &lt; 0 during the last year before inclusion (Brandt/Reinken 1988). Severe SGA (birth weight or length &lt; 4 SD) and clinically relevant dysmorphic features. Severe prematurity (GA &lt; 32 weeks of gestation). Severe perinatal complications like asphyxia, sepsis, necrotizing enterocolitis (NEC), respiratory distress syndrome, if associated with longterm sequelae (like short bowel syndrome, bronchopulmonary dysplasia (BPD), cerebral palsy etc). Inability to perform one or two leg jumps from a standing position. Prior GH treatment.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>